Literature DB >> 17896559

[Radiofrequency interstitial tumor ablation (RITA) for the treatment of localised prostate cancer].

M A Bonillo García1, V Gimeno Argente, J F Jiménez Cruz.   

Abstract

Radiofrequency ablation produces an irreversible destruction of prostate tissue since it reaches temperatures of 110 degrees C that leads the tumour into coagulative necrosis and, based on preliminary studies, it has shown to be a safe therapeutical alternative for localised prostate cancer. It is a non-invasive technique with scarce complications which is especially attractive for those patients whose co-morbidity precludes them from having any others procedures that require general anaesthesia or that make them to be admitted. Another valuable aspect of this treatment modality is that treatment times are short (less than 10 minutes), and controlled lesions can be predictably generated, as well as it is a feasible technique by most urologists since it requires only basic imaging experience and it could be also repeated at any time if needed. However, despite these promising results, long term follow-up are needed before conclusions about the efficacy of RITA can be drawn and, therefore, before setting its role in localised prostate cancer treatment.

Entities:  

Mesh:

Year:  2007        PMID: 17896559     DOI: 10.1016/s0210-4806(07)73699-9

Source DB:  PubMed          Journal:  Actas Urol Esp        ISSN: 0210-4806            Impact factor:   0.994


  2 in total

1.  [Radiofrequency ablation as minimally invasive treatment for tumors : a commentary on Schultheis et al].

Authors:  T Schneider; H Dienemann
Journal:  Chirurg       Date:  2008-10       Impact factor: 0.955

Review 2.  Follow-up modalities in focal therapy for prostate cancer: results from a Delphi consensus project.

Authors:  B G Muller; W van den Bos; M Brausi; J J Fütterer; S Ghai; P A Pinto; I V Popeneciu; T M de Reijke; C Robertson; J J M C H de la Rosette; S Scionti; B Turkbey; H Wijkstra; O Ukimura; T J Polascik
Journal:  World J Urol       Date:  2015-01-06       Impact factor: 4.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.